Charles Gerk, MD
Family Medicine · Sterling, CONPI 1194992768
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $16,917 of the $20,584 with a category attached, or 82.2%. 22 manufacturers reported payments, led by AstraZeneca at 34.6% of the total. Reporting peaked in 2019 at $8,658 and has fallen 96.5% since, to $302 in 2025. Among family medicine clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 136 payments — averaging $151.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$7K
- GSK$5K
- Midmark Corporation$4K
- Teva Pharmaceuticals USA, Inc.$3K
- Lilly USA, LLC$421
- Otsuka America Pharmaceutical, Inc.$181
- plus $839 from 16 others
What the payments were for
- Consulting fees$16,91782%
- Travel & lodging$1,3567%
- Food & beverage$2,31111%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 29 | $7,131 |
| GSK | 14 | $4,933 |
| Midmark Corporation | 7 | $4,278 |
| Teva Pharmaceuticals USA, Inc. | 1 | $2,800 |
| Lilly USA, LLC | 28 | $421 |
| Otsuka America Pharmaceutical, Inc. | 9 | $181 |
| Exact Sciences | 8 | $131 |
| Novo Nordisk | 8 | $130 |
| Merck | 8 | $120 |
| Pfizer | 4 | $83 |
| AbbVie | 4 | $72 |
| Sanofi Pasteur Inc. | 3 | $62 |
| Bayer | 2 | $35 |
| Amgen | 2 | $31 |
| Sanofi-aventis U.S. LLC | 2 | $28 |
| Regeneron Healthcare Solutions, Inc. | 1 | $24 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $23 |
| Biohaven Pharmaceuticals, Inc. | 1 | $22 |
| Johnson & Johnson | 1 | $21 |
| Novartis | 1 | $20 |
| Radius Health, Inc. | 1 | $20 |
| Inspire Medical Systems, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$4,537
- BREZTRI$2,688
How this compares
$20,584 in reported general payments places this provider in the 95th percentile of 2,079 family medicine providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 33 | $38,844 |
| MounjaroTirzepatide | 22 | $38,392 |
| EliquisApixaban | 68 | $36,314 |
| Xigduo XrDapaglifloz Propaned/Metformin | 30 | $35,929 |
| OzempicSemaglutide | 26 | $33,071 |
| XareltoRivaroxaban | 30 | $32,384 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 36 | $31,932 |
| FarxigaDapagliflozin Propanediol | 46 | $25,856 |
| SynjardyEmpagliflozin/Metformin Hcl | 21 | $24,997 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $18,220 |
| JardianceEmpagliflozin | 16 | $13,698 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 16 | $9,473 |
| Advair HfaFluticasone Propion/Salmeterol | 19 | $8,824 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $8,431 |
| Spiriva RespimatTiotropium Bromide | 13 | $8,076 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $421 | $77,23655 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $7,131 | $40,13573 claims |
| PfizerEliquis | $83 | $36,31468 claims |
| Novo NordiskOzempic | $130 | $33,07126 claims |
| Johnson & JohnsonXarelto | $21 | $32,38430 claims |
| GSKTrelegy Ellipta | $4,933 | $18,22021 claims |
| AbbVieSynthroid | $72 | $1,40425 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,079 family medicine providers in Colorado.
Other family medicine in Sterling
- Ethan LazarusDenver$688K
- Michael de NardisLarkspur$335K
- Matthew YoungColorado Springs$270K
- Mark DeutchmanDenver$258K
- Kari UusinarkausWoodland Park$254K
- Michael MeekerUsaf Academy$174K
- Carolynn Francavilla BrownLakewood$174K
- Lawrence AndrewsColorado Springs$102K
- Gregory MaederWestminster$95K
- Paul SimmonsGrand Junction$62K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.